- Home
- ALMU vs MNPR Comparison
ALMU vs MNPR Comparison
Compare ALMU & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMU
- MNPR
- Stock Information
- Founded
- ALMU 2019
- MNPR 2014
- Country
- ALMU United States
- MNPR United States
- Employees
- ALMU N/A
- MNPR N/A
- Industry
- ALMU Semiconductors
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ALMU Technology
- MNPR Health Care
- Exchange
- ALMU Nasdaq
- MNPR Nasdaq
- Market Cap
- ALMU 247.7M
- MNPR 209.3M
- IPO Year
- ALMU N/A
- MNPR 2019
- Fundamental
- Price
- ALMU $15.59
- MNPR $36.87
- Analyst Decision
- ALMU
- MNPR Strong Buy
- Analyst Count
- ALMU 0
- MNPR 7
- Target Price
- ALMU N/A
- MNPR $62.00
- AVG Volume (30 Days)
- ALMU 513.0K
- MNPR 62.1K
- Earning Date
- ALMU 08-07-2025
- MNPR 08-08-2025
- Dividend Yield
- ALMU N/A
- MNPR N/A
- EPS Growth
- ALMU N/A
- MNPR N/A
- EPS
- ALMU N/A
- MNPR N/A
- Revenue
- ALMU $3,627,488.00
- MNPR N/A
- Revenue This Year
- ALMU N/A
- MNPR N/A
- Revenue Next Year
- ALMU N/A
- MNPR N/A
- P/E Ratio
- ALMU N/A
- MNPR N/A
- Revenue Growth
- ALMU 335.67
- MNPR N/A
- 52 Week Low
- ALMU $2.50
- MNPR $1.72
- 52 Week High
- ALMU $19.50
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- ALMU N/A
- MNPR 52.95
- Support Level
- ALMU N/A
- MNPR $31.84
- Resistance Level
- ALMU N/A
- MNPR $42.00
- Average True Range (ATR)
- ALMU 0.00
- MNPR 2.66
- MACD
- ALMU 0.00
- MNPR 0.57
- Stochastic Oscillator
- ALMU 0.00
- MNPR 52.62
About ALMU Aeluma Inc. Common Stock
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.